{
    "nctId": "NCT02683083",
    "briefTitle": "Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients",
    "officialTitle": "Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study",
    "overallStatus": "COMPLETED",
    "conditions": "Healthy Volunteers, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\nSubjects will only be included in the study if they meet all of the following criteria:\n\n* Subjects who have given informed consent\n* Subjects that agree not to drink alcoholic beverages or use any drugs during the study\n* Subject with blood parameters within normal ranges\n* Age: at least 18 years old\n\nPatients will only be included in the study if they meet all of the following criteria:\n\n* Patients who have given informed consent\n* Patients that agree not to drink alcoholic beverages or use any drugs during the study\n* Age: at least 18 years old\n* Patients with local, locally advanced or metastatic HER2+ breast carcinoma as diagnosed on biopsied tissue by immunohistochemistry or fluorescence in situ hybridization (FISH).\n\nExclusion Criteria:\n\nPatients will not be included in the study if one of the following criteria applies:\n\n* Pregnant patients\n* Breast feeding patients\n* Patients with occupational exposure to ionizing irradiation\n* Patients with previous thyroid disorders\n* Patients that received radiolabeled compounds with a long half-life (\\>7h) for diagnostic or therapeutic purposes within the last 2 days.\n* Patients with absolute contra-indications for thyroid blockage with potassium iodide.\n* Patients with abnormal liver: ALT/AST \\> 2 times normal values; bilirubin \\> 1.5 time normal values.\n* Patients with abnormal kidney function: \\< 50 ml/min/1,73 m2\n* Patients with recent (\\< 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4) with diarrhea as major symptom\n* Patients with any serious active infection\n* Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical\n* Patients who cannot communicate reliably with the investigator\n* Patients who are unlikely to cooperate with the requirements of the study\n* Patients at increased risk of death from a pre-existing concurrent illness\n* Patients who participated already in this study\n* Patients who participated in a previous trial with Anti-HER2 VHH1\n\nSubjects will not be included in the study if one of the following criteria applies:\n\n* Pregnant subjects\n* Breast feeding subjects\n* Subjects with occupational exposure to ionizing irradiation\n* Subjects with clinical significant disease or on concomitant therapy (except contraception)\n* Subjects with previous thyroid disorders\n* Subjects that received radiolabeled compounds with a long half-life (\\>7h) for diagnostic or therapeutic purposes within the last 2 days.\n* Subjects with absolute contra-indications for thyroid blockage with potassium iodide.\n* Subjects with abnormal liver: ALT/AST \\> 2 times normal values; bilirubin \\> 1.5 time normal values.\n* Subjects with abnormal kidney function: \\< 50 ml/min/1,73 m2\n* Subjects with recent (\\< 1 week) gastrointestinal disorders (CTCAE v4.0 grade 3 or 4) with diarrhea as major symptom\n* Subjects with any serious active infection\n* Subjects who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise subject safety or interfere with the evaluation of the safety of the test radiopharmaceutical\n* Subjects who cannot communicate reliably with the investigator\n* Subjects who are unlikely to cooperate with the requirements of the study\n* Subjects at increased risk of death from a pre-existing concurrent illness\n* Subjects who participated already in this study\n* Subjects who participated in a previous trial with Anti-HER2 VHH1",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}